To support the use of this formulation in a clinical trial aiming at treating light chain and transthyretin cardiac amyloidosis, the quality performances of the capsules and bioavailability of EGCG eutectic solution have been assessed. This evidence concerns the gene TTR and cardiac amyloidosis.